Literature DB >> 2434018

An antiestrogenic action of interferons in human breast cancer cells.

S Iacobelli, C Natoli, E Arnò, G Sbarigia, C Gaggini.   

Abstract

The antiproliferative and antiestrogenic effects of human interferon on estrogen-dependent CG-5 human breast cancer cells in vitro are reported. Fibroblast beta - interferon as well as recombinant alpha - and gamma -interferon inhibited proliferation of CG-5 cells in a dose and time - dependent fashion. In addition, they completely suppressed the two-fold increase in cell number induced by estradiol and showed an additive antiproliferative effect when used in combination with the antiestrogen tamoxifen. These antiestrogenic effects of interferons were accompanied by a reduced receptor binding of estradiol to the cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2434018

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer.

Authors:  F Porzsolt; A M Otto; B Trauschel; C Buck; A W Wawer; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

2.  Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer.

Authors:  J E Macheledt; A U Buzdar; G N Hortobagyi; D K Frye; J U Gutterman; F A Holmes
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

3.  Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.

Authors:  D F Gibson; D A Johnson; D Goldstein; S M Langan-Fahey; E C Borden; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

4.  Megestrol acetate plus alpha 2a interferon as second line therapy for postmenopausal patients with advanced breast cancer: results of a multicentric phase II trial.

Authors:  D Amoroso; F Boccardo; M Balestrero; L Miglietta; F Brema; R Cellerino; A Farris; U Folco; S Iacobelli; M Mesiti
Journal:  Breast Cancer Res Treat       Date:  1995-03       Impact factor: 4.872

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.